CAM
KALV

Cormorant Asset Management’s KalVista Pharmaceuticals KALV Stock Holding History

Cormorant Asset Management’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-750,000
Closed -$19.3M – 115
2021
Q1 		$19.3M Buy
+750,000
New +$19.7M 0.43% 53

Other funds holding KALV

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Cormorant Asset Management's KALV Position: Q2 2021 in Review

Cormorant Asset Management sold out of KalVista Pharmaceuticals (KALV) in Q2 2021, closing a stake of 750,000 shares — an estimated $19.3M sold.

Cormorant Asset Management first reported a position in KALV in Q1 2021 and held it in 1 quarter. The position peaked at $19.3M in Q1 2021. 110 funds tracked by Wall St. Rank hold KALV as of Q2 2021.

  • Cormorant Asset Management reported no remaining KalVista Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • Cormorant Asset Management sold 750,000 KalVista Pharmaceuticals shares in Q2 2021, an estimated $19.3M.
  • Cormorant Asset Management first reported a position in KalVista Pharmaceuticals in Q1 2021 and held it in 1 quarter.
  • Cormorant Asset Management's KalVista Pharmaceuticals position peaked at $19.3M in Q1 2021.
  • 110 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q2 2021.

Based on Cormorant Asset Management's 13F filing for Q2 2021, filed 16 Aug 2021.